Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
about
Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable)Concurrent chemoradiotherapy in non-small cell lung cancerStereotactic body radiotherapy in lung cancer: an updateRadiation dose effect in locally advanced non-small cell lung cancerExploiting biological and physical determinants of radiotherapy toxicity to individualize treatmentDefinitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionationChronic radiation-induced dermatitis: challenges and solutionsChallenges in the treatment of early non-small cell lung cancer: what is the standard, what are the challenges and what is the future for radiotherapy?Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complicationsRadical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancerProliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice.Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancerEpidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results.The impact of PET/CT scanning on the size of target volumes, radiation exposure of organs at risk, TCP and NTCP, in the radiotherapy planning of non-small cell lung cancer.Cancer gene therapy: developments to 2000.Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable).Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic reviewHyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.Outcomes of accelerated hypofractionated radiotherapy in stage i non-small-cell lung cancer.Dose escalated, hypofractionated radiotherapy using helical tomotherapy for inoperable non-small cell lung cancer: preliminary results of a risk-stratified phase I dose escalation studyAre cancer stem cells radioresistant?A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer.Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase IIState of the art in therapy for non-small cell lung cancer.21 years of biologically effective doseCPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II.Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysisAccelerated regrowth of non-small-cell lung tumours after induction chemotherapy.DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer.Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy.Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerEarly and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damageDose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial.Combination of radiotherapy and chemotherapy in locally advanced NSCLC.Therapeutic management options for stage III non-small cell lung cancer.
P2860
Q24187481-F49F0905-D6E7-4D08-A4C2-D061B4C6B2EDQ24234963-29C956C9-5B9D-4EDF-85E8-3CC197A60228Q26781806-6729271F-EE89-488B-B755-A4724810665CQ26823043-166E23D6-7E72-4E44-8BEC-85156EF74F58Q26849735-4670F8A2-D301-4380-ABEE-F433056D9DDCQ27027626-372D951C-8978-408E-8039-5075B5BA5FA7Q28069969-92BA48BB-3FC8-4F8D-AC59-33EEE50B276BQ28083924-1DE24288-9EE8-4C51-9027-69B62F80192EQ28282290-717E34C9-1702-42A7-B3A4-F27856108120Q30857091-B073D717-B702-42FB-A5F0-4C6EE89337E6Q33193703-526E1AA9-1DC3-441F-A95B-45E1BF703FBFQ33349702-1C4B0EF0-3F65-4AFA-BE1C-C9ADCC9E3CB1Q33353609-8477F0A2-0974-4B22-B072-A78811D2C68AQ33760747-5A9140F5-7DE5-4441-BED4-43354EE0E5C2Q34090963-57C1C0FC-9601-470A-858D-A9392B8A1A63Q34202691-B063AC19-DC27-49E0-868B-7E66CD6EBF45Q34312788-C6D71581-1733-42B2-BEAE-BDC4D8A5C99BQ34323959-373684F2-4547-4A8B-87A0-3F1C4463E9EAQ34372246-92B93C5F-C145-475C-BEF3-C2712CC5684EQ34610601-E6E9758B-D7EB-4D78-A255-AF5A21337E3EQ34686233-7A85F849-12C6-47E8-B8EE-CD8DBA459C94Q35290601-14426E89-5847-4971-A7B4-EFBCE494E2EDQ35669846-197BE733-B76D-4D10-9B0E-B4CCD548A474Q35848165-CE47179D-B884-4E3B-9780-17C6BD204A2AQ35939945-E016D6A0-C226-42F7-A07D-82EBA96F2D0BQ35997579-CC0EE9E3-B622-4BC3-A139-06E9AE27ABDFQ36271949-B9D47B50-9830-4E95-A173-F43A5C6C276BQ36324701-39BF5C18-76D9-453B-A371-18D4CDBF9E51Q36611654-61ED5776-F1B1-426E-83F2-E7B05F5574C5Q36643619-72C65B30-9BD3-443A-A47A-8A8C00BEF81FQ36673537-DB02A6F9-4620-4B1E-AA9A-C0E64A909579Q36710620-8C389EC5-AE9D-4059-982F-D9B9C3774555Q36874790-7D6241A7-3656-4E22-AECD-091EAB9AB38CQ36958517-09E5D6A7-68CA-4ECD-8F48-98317546E642Q36989648-6A3EA1CA-6D3E-4B19-AC6C-0CCB5BE8CB50Q36991603-B3BBD989-148D-4340-BAB4-80EF3BD4AAE3Q37333649-BDEF88C3-FD90-4ECA-9FDC-1DFECD9ED364Q37417131-EB419B14-332B-4176-9A19-F39AD328C3A9Q37614572-47EE54C8-E1A1-409A-A8BB-980B87C3F3DFQ37642455-6B0D612B-EAFA-4844-930A-C388248E73BE
P2860
Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@ast
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@en
type
label
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@ast
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@en
prefLabel
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@ast
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@en
P2093
P1476
Continuous, hyperfractionated, ...... ial. CHART Steering committee.
@en
P2093
P304
P356
10.1016/S0167-8140(99)00087-0
P577
1999-08-01T00:00:00Z